Abstract
To compare 12-month rates of discontinuation (primary outcome), user satisfaction and adverse events (AEs) (secondary outcomes) associated with the use of a new 13.5 mg (total content) levonorgestrel intrauterine contraceptive system (LNG-IUS 13.5 mg; Jaydess®) and the etonogestrel subdermal contraceptive implant (ENG implant, Nexplanon®).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have